
In this lesson on glycoprotein (GP) IIb/IIIa (GPIIb/IIIa) inhibitors, you’ll learn the high-yield, test-relevant concepts behind the adjunct antiplatelet drug therapy used in the acute management of patients experiencing an acute myocardial infarction (AMI; NSTEMI, STEMI) and undergoing PCI or coronary stent placement. In this lecture from This is Why, Dr. Busti will break down how platelet aggregation inhibitors work, when they’re used clinically, and the key differences between tirofiban and eptifibatide —so you can apply the “why” behind therapy (not just memorize drug names).
You’ll learn how to:
- The GPIIb/IIIa receptor and how blocking it reduces platelet activation
- Where GPIIb/IIIa inhibitors fit in clinical practice
- High-yield uses: acute coronary syndrome (ACS) and PCI/stents
- Major adverse effects (including bleeding) and top safety pearls
The goal = make medical education easy and clinically relevant.
Chapter Table of Contents
00:00 - Introduction to GPllb/llla Inhibitors
01:48 - Agents
02:31 - Indications & Uses
03:08 - Net Benefit
06:46 - Pharmacology
10:31 - Clinical Knowledge
15:35 - Summary
If this helped you, please like, subscribe to our YouTube Channel, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.
Don’t forget to turn on notifications on YouTube so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!
#gpiibiiiainhibitors #tirofiban #antiplateletpharmacology #eptifibatide #drbusti
Speaker:
Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.
Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.
About This Channel:
This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

GPIIb/IIIa Inhibitors: Antiplatelet Pharmacology Made Easy & Relevant
GPIIb/IIIa Inhibitors: Antiplatelet Pharmacology Made Easy & Relevant